"FDA Approves First Immunotherapy Drug for Triple-Negative Breast Cancer" - Kristen Fischer
Until now, people with inoperable triple-negative breast cancer had one treatment option: chemotherapy. But this month, the FDA granted accelerated approval to the first immunotherapy treatment for breast cancer. It combines the drug atezolizumab with a form of chemotherapy. Amy Tierstein, MD, a breast oncologist at the Dubin Breast Center at the Tisch Cancer Institute at Mount Sinai, was thrilled about the drug’s approval and said it should be covered by insurance. About one-fifth of people with triple negative breast cancer have the PD-L1 protein, which is what atezolizumab targets.
— Amy Tiersten, MD, Professor, Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, Oncologist, Breast Cancer Medical Oncology Program, The Dubin Breast Center, The Mount Sinai Hospital